Europe Continuous Bioprocessing Market - By Technology: Continuous Upstream Bioprocessing (Perfusion Bioreactors), Continuous Downstream Bioprocessing (Chromatography, Filtration), Integrated Continuous Biomanufacturing (ICB), Process Analytical Technologies (PAT); By Product Type: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell and Gene Therapy Products; By Country: Germany, United Kingdom, France, Spain, Italy, Russia, Rest of Europe
1 | Market Overview
The European continuous bioprocessing market involves the adoption of uninterrupted, integrated biomanufacturing technologies for the production of biologics, vaccines, and cell and gene therapies. Unlike traditional batch processing, continuous bioprocessing enables real-time production control, reduces footprint, lowers costs, and accelerates time-to-market for biopharmaceuticals.
Europe’s biologics manufacturing industry is increasingly adopting continuous bioprocessing to enhance efficiency and satisfy the rising demand for monoclonal antibodies (mAbs), recombinant proteins, and personalized medicine. This transition is bolstered by innovations in single-use systems, perfusion bioreactors, continuous chromatography, and process analytics.
2 | Market Size and Forecast
|
Year |
Market Value (USD Million) |
Notes |
|
2019 |
490 |
Driven by perfusion and PAT adoption |
|
2024 |
770 |
CAGR 9.5% (2019–2024) |
|
2031 |
1,780 |
Projected CAGR 12.4% (2024–2031) |
3 | Drivers & Challenges
Drivers:
Challenges:
4 | Segment Insights
By Technology:
By Product Type:
5 | Regional Insights
6 | Competitive Landscape
Leading players include: Sartorius AG, Merck KGaA, GE Healthcare, Thermo Fisher Scientific, Lonza, Cytiva, MilliporeSigma, Pall Corporation, and Repligen.
Focus areas:
Need help?
Chat with our team in a minute.